Shadow AI in Pharma: Govern the Access Path Before Data Moves

A deviation summary needs drafting before the end of a shift, the approved process is slow, and someone reaches for the AI tool that is already open.

The useful question is rarely, “Which AI tool was used?” The better question is: what route did the data take, and could anyone control it before sensitive information had already left?

“Tool approval often gets treated as the control. In practice, it is only the start.”

A tool can be approved and still be poorly governed until someone has defined what data it can access, what it can retain, which identity it acts under, which connector it can use, and what evidence remains afterwards.

In Life Sciences, that route has to be owned, limited, monitored, approved, changed, retired, and evidenced. This applies whether the workflow supports pharmaceutical manufacturing, clinical development, pharmacovigilance, quality operations, or proprietary research.

This is the same control problem raised in MIGx’s earlier article on the risks of AI in Life Sciences. Building or buying AI works only when governance, validation, and supplier oversight remain close to the actual use case.

Shadow AI in Pharma Is a Workflow Signal

When the Approved Route Is Too Slow

Shadow AI in Pharma usually starts with a real business need. Someone needs to summarise, draft, search, compare, translate, classify, or clean up text. If the approved process is too slow, too restricted, or ownership is unclear, people will find another way.

That behaviour is a design signal. It shows that the control has missed the workflow.

Blocking public AI endpoints may reduce visible usage, but the work still exists. A stricter policy may move the behaviour into a personal account, a browser extension, a copied dataset, or a tool outside the review process.

The data movement then becomes invisible to the people who need to see it in order to govern it. In a pharmaceutical environment, that hidden route may involve deviation records, clinical information, safety narratives, validation documents, or commercially sensitive research.

The answer is an approved path that is fast enough to use, with clear boundaries around data classification, identity, connectors, permitted actions, retention, and approval..

Why Tool Approval Alone Cannot Stop Shadow AI Data Leakage

“Approved by IT” is a label. The boundary still has to be designed.

Tool Approval vs. Data Boundary Controls in Pharma

Addressing Shadow AI in pharma effectively means recognising that an approved assistant can still create exposure if it retrieves too much, retains too much, or sends information into an environment designed for a different data classification.

An enterprise AI service may offer stronger controls than a consumer chatbot, but the label becomes meaningful only when the organisation understands the logs, conversation history, administrative access, abuse monitoring, contract terms, retention, deletion, data residency, subprocessors, and audit evidence.

For low risk drafting, provider commitments and appropriate configuration may be sufficient. For identifiable patient data, regulated evidence, clinical study context, or proprietary research, the follow-up questions need to be much sharper.

What exactly entered the system? Where was it processed? Can it be recovered, deleted, or evidenced under the actual service configuration and contract terms?

For identifiable patient or health data, strict containment should remain the default. External AI services belong in these workflows only when the environment, contract, validation approach, auditability, privacy review, supplier obligations, data transfer position, and technical controls were designed for that data class.

In practice, this means minimising the information shared, masking or pseudonymising data where appropriate, separating patient data systems, and using data loss prevention controls that can reduce, block, or flag sensitive content before it reaches unmanaged AI endpoints.

“If the question “Where exactly did that patient text go?” makes the room uncomfortable, the control needs to be stronger.”

How AI Agents Change the Risk Profile in Pharma

AI risk changes when the assistant stops behaving like a text box and begins acting through connectors, credentials, workflows, plugins, or internal systems.

An agent that retrieves records, opens a service ticket, drafts a regulated response, or triggers a workflow is acting with delegated authority. Whether it acts through delegated user access, a workload identity, a service account, or its own runtime identity, the fundamental question remains the same.

What can this actor do, for whom, under which conditions, and with what audit trail?

In Pharma, that route may reach a clinical narrative, a safety case, a validation artefact, batch release context, or supporting evidence. If the agent changes regulated content, the question becomes one of validation impact, approval authority, and audit evidence.

At that point, productivity is no longer the metric that matters most.

Managing Shadow AI in Pharma: Policy Has to Follow the Action

If an assistant connected to document repositories, regulated records, validation folders, ticketing workflows, or clinical documentation retrieves information on behalf of a user, the login event is only the beginning.

The policy decision has to follow the delegated action. Which user initiated it? Which agent performed it? Which connector was used? Which environment was involved? Which data classification applied? Which action was requested? Which business context justified it?

NIST’s Zero Trust Architecture makes the same point for infrastructure generally. Organisations should stop trusting network location and evaluate individual requests on their own terms.

The Zero Trust implication for AI agents is straightforward. A successful login authorises the start of a session. It should not automatically authorise every delegated action that follows.

• Least privilege defines both what the user can access and what the agent can access on the user’s behalf.
• Separation of duties must continue to apply when work is delegated to an AI agent.
• Access policy, data loss prevention, workload identity controls, connector allow listing, and transaction-level approval should evaluate identity, data context, environment, and action together.
• Human approval should remain in front of regulated record modification. If manual clean-up becomes the normal control, the design needs to be reviewed.

The flow below shows the access decision in one picture: agent identity, data classification, allowed capability, human approval where required, and one audit trail.

The Cloud Security Alliance makes the same data movement case for healthcare. Simple allow or block thinking is too blunt once sensitive information can move through AI tools. OWASP makes the identity point from the agent side. An agent with unclear privileges can become an abuse path. In Life Sciences, those two threads meet in a more serious place. The same failure can affect a clinical record, safety case, validation artefact, or batch release decision.

A Pre-Pilot Review Using NIST’s AI Risk Management Framework

These questions belong in the room before the pilot quietly turns into the tool everyone depends on.

Use the NIST AI Risk Management Framework as the starting point by working through Govern, Map, Measure, and Manage. For Life Sciences organisations, that assessment also needs to consider the evidence required to support audits, inspections, change control, and data integrity throughout the AI lifecycle.

• Govern: Who owns the use case, agent identity, approval path, supplier review, residual risk, and kill switch?
• Map: Which users, systems, connectors, data classes, jurisdictions, regulated records, and downstream decisions are involved?
• Measure: What can go wrong, and how would anyone know? Test wrong data, wrong answer, and wrong context, along with prompt injection, over-permissioned access, missing audit trails, data leakage, and validation impact before the tool becomes business critical.
• Manage: Which controls enforce the decision? Can the identity be disabled, the connector blocked, the secret rotated, or the workflow quarantined quickly?
• Evidence: Can the organisation trace who submitted the request, which agent acted, what it accessed, what it produced, who approved it, what changed, and why the result was considered acceptable?

The practical next step is straightforward. Select one real AI workflow, map the access route, assign an owner, test patient and regulated data handling, and verify the kill switch before the pilot becomes normal business practice.

Data Integrity and Regulatory Compliance Risks in Life Sciences

In Life Sciences, confidentiality is only the starting concern. The data, the decision, and the supporting evidence all need to withstand future scrutiny.

Manufacturing, clinical, safety, validation, and privacy teams answer different questions. Each function needs a defined route into the approval decision. Health-related data also raises the control expectation, whether an organisation is working under European, Swiss, or US privacy requirements.

The European regulatory direction and US regulatory direction point towards the same operational message: AI governance depends on appropriate documentation, human oversight, lifecycle control, and evidence that can withstand regulatory scrutiny. For Life Sciences organisations, the challenge is not waiting for future guidance. It is implementing those principles in the AI systems already being used today.

Return to the deviation summary from the introduction. If an inspector asks about it six months later, saying that “an AI tool helped draft it” is an incomplete answer.

The real questions are more specific. Which model or service produced the draft? What source records did it access? Who reviewed the draft against the source evidence before approval? Can that chain still be traced, reconstructed, reviewed, and evidenced today?

That is what regulated data integrity means once AI becomes part of the workflow. The record has to remain defensible when an inspector questions it months later.

Operationalizing AI Governance for Life Sciences with MIGx

MIGx helps Life Sciences teams turn AI governance into operational controls. This includes mapping the real workflow before a pilot becomes a production dependency, defining the access route across users, agents, connectors, data classes, and approval points, and building evidence that can withstand audit, inspection, and incident review.

Secure the Data Path to Eliminate Shadow AI Risk

Shadow AI in Pharma and approved AI ultimately fail for the same reason. Organisations stop at tool approval instead of governing the route underneath it.

The real control point is the route itself: which data can be accessed, under which identity, through which connector, for which action, and with what evidence afterwards.

For regulated Life Sciences organisations, AI governance is no longer about deciding whether people will use AI. It is about ensuring every AI-assisted workflow remains controlled, traceable, and defensible.